Epic Sciences

MedTech, Industrial Impact

SOPHiA GENETICS | March 01, 2023

On February 28, 2023, SOPHiA GENETICS, a leading cloud-native software solutions provider in the healthcare space, announced that Synergy Oncology, a part of Synergy Laboratories based in Mobile, Alabama, will utilize SOPHiA DDM™ to develop a new cancer profiling solution. Synergy Oncology is a specialist in innovative platforms that improve patient care. The use of SOPHiA DDM™ for Hereditary Cancers Solution in Synergy Oncology's state-of-the-art laboratory tech...

Industrial Impact, Medical

Celularity | January 17, 2023

Celularity Inc., a biotechnology firm based in the United States that develops placental-derived allogenic cell treatments and biomaterials, and CH Trading Group LLC, an international import, export, and trading corporation, have agreed to an exclusive territorial distribution agreement. CH Trading Group will serve as the exclusive territorial distributor for halal-certified products previously announced by Celularity in over 100 countries. The product distribution agreement for...

GenScript | June 03, 2020

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Cell and Gene Therapy

Solvias | January 23, 2024

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older wit...